ACTH therapy benefits stuttering and autism

Aug 30, 2018 | Autism Science and Research News

Adrenocorticotropic hormone therapy in patients with nighttime subclinical seizure activity improves their stuttering and autism symptoms

ACTH therapy improves core symptoms of autism alongside EEG parameters and sublinical seizures.

In a retrospective study a total of 25 patients with attention deficit and hyperactivity (ADHD) or autism spectrum and comorbid stuttering were followed and treated with adrenocorticotropic hormone (ACTH) for electrical status epilepticus in sleep (ESES). Following treatment with ACTH, normalisation of EEG parameters and subclinical epileptiform activity in all the patients was accompanied by a 72% improvement in ADHD or autism symptoms, and 83.8% improvement in stuttering. Twelve of the 25 patients with stuttering showed complete treatment response. The authors noted that the improvement in stuttering had a positive correlation with improvement in ADHD or autism symptoms.

“Following treatment with ACTH, a reduction in spike–wave index (SWI) in all the patients was accompanied by a 72% improvement in ADHD or ASD, and 83.8% improvement in stuttering. Twelve of the 25 patients with stuttering showed complete treatment response. Linear regressions established that SWI at final visit significantly predicted improvement in ADHD or ASD, and in stuttering.

“Stuttering shows a high rate of comorbidity with other developmental disorders such as ADHD and ASD. Language related symptoms in patients with benign focal epilepsies of childhood and LKS also involve stuttering…

The literature reports ESES activity in various developmental disorders. Abnormal epileptiform activities in ADHD/ASD patients have been documented, with an overall prevalence of epileptiform discharges ranging from 14% to 83% in various studies.

Our previous study illustrates that the onset or recurrence of ADHD symptoms is associated with the progressing epileptiform activity; when SWI is around 10–15%, neuropsychiatric symptoms appear. The underlying etiology may play a significant role in the pathophysiology of ESES, stuttering and other comorbidities, thereby connecting ESES to other developmental disorders.

According to the literature enhanced epileptiform activity is associated with cognitive and behavioral impairment while treatment with hormonal therapy is reported to improve language, cognition and behavior.

References:

Altunel A, Sever A, & Altunel EÖ. (2017) ACTH has beneficial effects on stuttering in ADHD and ASD patients with ESES: A retrospective study. Brain Dev. Feb;39(2):130-137. doi: 10.1016/j.braindev.2016.09.001..

 

Century-old drug offers new hope for autism treatment

A small double-blind, placebo-controlled trial shows dramatic effects of suramin as a treatment for autism. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all who received the active treatments, absent in the placebo arm

Autistic regression linked to autoimmunity

Autistic regression is a phenomenon where a previously normally developing child loses developmental milestones and previously acquired language and social skills, and regresses into autism. Symptoms such as fever, vomiting, incessant crying, irritability, changes in sleep patterns and emergence of motor abnormalities are frequently noted around the time of autistic regression…

Autism Action Month: 12-month autism research recap 2018

We chose to call April Autism Action month, in large part because there is plenty of general awareness. Given the skyrocketing rates, it’s difficult to find an adult who doesn’t know a child with autism. However, there ought to be vast improvements when it comes to autism research awareness. With that in mind, below is our quick overview of important autism research (action!) from the past 12 months.

Connect with us on social media

DISCLAIMER The purpose of this site is to provide information. No information on this website should be construed as medical advice. Neither article authors, associated charities, nor individual contributors take any responsibility or liability for any decision taken by site visitors as a result of the information contained herein or the external links provided. If you need medical advice, please seek it from a suitably qualified practitioner.
© 2018 Thinking Autism | All rights reserved | Registered Charity: No. 1113628, Limited Company Registered in England: No. 5594787

Share this page

Share this content with your friends or colleagues